Comparison of two detection systems for circulating tumor cells among patients with renal cell carcinoma
- 235 Downloads
Detection of circulating tumor cells (CTCs) in cancer patients has diagnostic and prognostic importance. However, the clinical implications of CTC detection in patients with renal cell carcinoma (RCC) are still unclear. In this study, we investigated the clinical significance of CTCs using two detection systems, the CellSearch system (CSS) and isolation by size of epithelial tumor cells (ISET), among RCC patients.
We recruited 36 RCC patients and 22 healthy volunteers as controls. Blood was drawn before treatment. Samples were analyzed using the CSS and ISET. We prospectively followed the RCC patients to determine overall and progression-free survival.
We did not detect CTCs in the control group using either the CSS or ISET. CTCs were detected in 7/36 patients (19.4%) using the CSS and in 13/36 patients (36.1%) using ISET, while circulating microemboli (CTMs) were detected in three patients (8.3%). The presence of ISET-detected CTCs correlated with clinical tumor node metastasis (TNM) stages, while the CSS-detected CTCs did not. After 36 months (median), CTCs detected by both methods failed to correlate with overall and progression-free survival among RCC patients.
We discovered that ISET is more suitable than the CSS for detecting CTCs in RCC patients. The presence of CTCs/CTMs in RCC patients correlated with higher TNM stages, suggesting that the presence of CTCs could be a prognostic marker in RCC patients.
KeywordsRenal cell carcinoma Circulating tumor cell CellSearch Isolation by size of epithelial tumor cell Prognosis
This study was supported by the project of major innovation and technology sponsored by the Department of Science and Technology of Shandong Province (Grant Number: 2017CXGC1204). Sincere acknowledgements are given to Dr. Zuowei Lu and Dr. Min Liu for assistance with cytopathologic analysis. The authors would also like to thank Wuhan YZY Medical Technological Co. Ltd. and United States Johnson & Johnson Medical Companies for their outstanding technical support.
Compliance with ethical standards
Conflict of interest
The authors declared that they have no conflict of interest to this work.
This study was approved by the ethical review board of Shandong Cancer Hospital and Institute (approval number: 201405002) and complied with the Helsinki declaration.
Written informed consent was obtained from all participants.
- 5.Allard WJ, Matera J, Miller MC et al (2005) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10:6897–6904. https://doi.org/10.1158/1078-0432.CCR-04-0378 CrossRefGoogle Scholar
- 14.Hofman V, Bonnetaud C, Ilie MI et al (2011) Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer Res 17:827–835. https://doi.org/10.1158/1078-0432.CCR-10-0445 CrossRefPubMedGoogle Scholar
- 17.Ashworth TR (1869) A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J 14:146Google Scholar
- 18.McKiernan JM, Buttyan R, Bander NH, de la Taille A, Stifelman MD, Emanuel ER, Bagiella E, Rubin MA, Katz AE, Olsson CASI (1999) The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9. Cancer 86:492–497CrossRefPubMedGoogle Scholar
- 23.Zimpfer A, Maruschke M, Rehn S et al (2014) Prognostic and diagnostic implications of epithelial cell adhesion/activating molecule (EpCAM) expression in renal tumours: a retrospective clinicopathological study of 948 cases using tissue microarrays. BJU Int 114:296–302. https://doi.org/10.1111/bju.12487 CrossRefPubMedGoogle Scholar